Maviret
(Glecaprevir/Pibrentasvir)Phase 3Small molecule
AbbVieThis drug is used to treat hepatitis C virus (HCV) infection. It works by stopping the virus from reproducing in the body, potentially curing the infection.[1] Maviret is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Maviret is one of 61 small molecule programs targeting Drug. It is currently in Phase 3.
2
Indications
27
Total Trials
3
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Sovaldi
GileadApproved
Actos
TakedaApproved
Selzentry
GSKApproved
Afinitor
NovartisApproved
Neoral
NovartisApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Prograf
VVeloxis Pharmaceuticals
Approved
Trental
VValidus Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Remeron
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatitis C9 trials
Chronic Hepatitis8 trials
Show 5 more trials
Kidney Transplant3 trials
5 more indications
Randomized1 trial
Treatment1 trial
Hepatitis C Virus Infection1 trial
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT04042740·45 enrolled
Drug1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glecaprevir/Pibrentasvir. EMBL-EBI & Wellcome Sanger Institute.
- [4]